Decibel Therapeutics, Inc. EBITDA
Decibel Therapeutics, Inc. EBITDA
- 2023-06-30: Basis Reported; EBITDA (m); Operating income -$19.04M; Depreciation and amortization (m).
- 2023-03-31: Basis Reported; EBITDA (m); Operating income -$14.12M; Depreciation and amortization (m).
- 2022-09-30: Basis Reported; EBITDA (m); Operating income -$16.35M; Depreciation and amortization (m).
- 2022-06-30: Basis Reported; EBITDA (m); Operating income -$17.10M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2023-06-30 | Reported | (m) | -$19.04M | (m) | (m) | (m) | (m) | (m) | (m) | $12.83M | (m) | $80.00K |
|---|
| 2023-03-31 | Reported | (m) | -$14.12M | (m) | (m) | (m) | $266.00K | -$17.06M | (m) | $7.93M | (m) | $61.00K |
|---|
| 2022-09-30 | Reported | (m) | -$16.35M | (m) | (m) | (m) | (m) | (m) | (m) | $10.03M | (m) | $30.00K |
|---|
| 2022-06-30 | Reported | (m) | -$17.10M | (m) | (m) | (m) | (m) | (m) | (m) | $11.24M | (m) | $38.00K |
|---|
| 2022-03-31 | Reported | (m) | -$14.02M | (m) | (m) | (m) | $101.00K | -$22.01M | (m) | $7.47M | (m) | $60.00K |
|---|
| 2021-09-30 | Reported | (m) | -$14.70M | (m) | (m) | (m) | (m) | (m) | (m) | $9.02M | (m) | $1.73M |
|---|
| 2021-06-30 | Reported | (m) | -$11.73M | (m) | (m) | (m) | (m) | (m) | (m) | $6.83M | (m) | $0.00 |
|---|
| 2021-03-31 | Reported | (m) | -$10.90M | (m) | (m) | (m) | $65.00K | -$16.31M | (m) | $6.02M | (m) | $0.00 |
|---|
| 2020-09-30 | Reported | (m) | -$7.09M | (m) | (m) | (m) | (m) | (m) | (m) | $4.69M | (m) | $0.00 |
|---|
| 2020-06-30 | Reported | (m) | -$7.85M | (m) | (m) | (m) | (m) | (m) | (m) | $5.30M | (m) | (m) |
|---|
| 2020-03-31 | Reported | (m) | -$11.61M | (m) | (m) | (m) | $56.00K | -$11.91M | (m) | $7.44M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2022-12-31 | Reported | -$62.46M* | -$63.96M | $1.50M | (m) | (m) | $463.00K | -$56.90M | (m) | $40.33M | (m) | $240.00K |
|---|
| 2021-12-31 | Reported | -$48.83M* | -$50.23M | $1.40M | (m) | (m) | $745.00K | -$43.15M | (m) | $29.85M | (m) | $1.80M |
|---|
| 2020-12-31 | Reported | -$37.96M* | -$39.56M | $1.60M | (m) | (m) | $273.00K | -$32.66M | (m) | $25.32M | (m) | $0.00 |
|---|